Back Our latest news News selection Discover below our latest news and publications related to our oncology compounds and antibiotics. Press releases June 3, 2024 Debiopharm and Genome & Company Reach Agreement for Potential First-In Class Oncology Antibody Drug Conjugate Family Read more May 28, 2024 MEDSIR & DEBIOPHARM Initiate Clinical Collaboration to Explore Potential Synergy of Debio 0123 & Sacituzumab Govitecan in Advanced Breast Cancer Read more April 30, 2024 Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1B Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1… Read more All Press Releases Publications June 26, 2024 Population PK and Exposure-Response Modeling to Support the Design of Trials with DEBIO 0123, a WEE1 Inhibitor, in Cancer Patients Read more May 31, 2024 Results of a Phase 1, Dose-finding Study of Debio 0123 as Monotherapy in Adult Patients with Advanced Solid Tumors –… Read more May 14, 2024 Exploring the content and psychometric validity of clinical outcome assessments in pancreatic ductal adenocarcinoma versus the patient reported symptoms and… Read more All Publications About us Partner with us Product focus Digital Health Our latest news Pipeline